107 related articles for article (PubMed ID: 17365652)
21. Nanoscopic cell-wall architecture of an immunogenic ligand in Candida albicans during antifungal drug treatment.
Lin J; Wester MJ; Graus MS; Lidke KA; Neumann AK
Mol Biol Cell; 2016 Mar; 27(6):1002-14. PubMed ID: 26792838
[TBL] [Abstract][Full Text] [Related]
22. Analysis of beta-1,3-glucan assembly in Saccharomyces cerevisiae using a synthetic interaction network and altered sensitivity to caspofungin.
Lesage G; Sdicu AM; Ménard P; Shapiro J; Hussein S; Bussey H
Genetics; 2004 May; 167(1):35-49. PubMed ID: 15166135
[TBL] [Abstract][Full Text] [Related]
23. Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways.
Wiederhold NP; Kontoyiannis DP; Prince RA; Lewis RE
Antimicrob Agents Chemother; 2005 Dec; 49(12):5146-8. PubMed ID: 16304189
[TBL] [Abstract][Full Text] [Related]
24. Exposure to caspofungin activates Cap and Hog pathways in Candida albicans.
Kelly J; Rowan R; McCann M; Kavanagh K
Med Mycol; 2009 Nov; 47(7):697-706. PubMed ID: 19888802
[TBL] [Abstract][Full Text] [Related]
25. Interactions of liposome carriers with infectious fungal hyphae reveals the role of β-glucans.
Chavan NL; Young JK; Drezek RA; Lewis R; Bikram M
Mol Pharm; 2012 Sep; 9(9):2489-96. PubMed ID: 22770505
[TBL] [Abstract][Full Text] [Related]
26. Glucan synthesis and its inhibition by cilofungin in susceptible and resistant strains of Candida albicans.
Angiolella L; Bromuro C; Simonetti N; Cassone A
J Med Vet Mycol; 1992; 30(5):369-76. PubMed ID: 1469538
[TBL] [Abstract][Full Text] [Related]
27. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y
Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
[TBL] [Abstract][Full Text] [Related]
28. Proteomic analysis of proteins released from growth-arrested Candida albicans following exposure to caspofungin.
Kelly J; Kavanagh K
Med Mycol; 2010 Jun; 48(4):598-605. PubMed ID: 20392151
[TBL] [Abstract][Full Text] [Related]
29. The cell wall architecture of Candida albicans wild-type cells and cell wall-defective mutants.
Kapteyn JC; Hoyer LL; Hecht JE; Müller WH; Andel A; Verkleij AJ; Makarow M; Van Den Ende H; Klis FM
Mol Microbiol; 2000 Feb; 35(3):601-11. PubMed ID: 10672182
[TBL] [Abstract][Full Text] [Related]
30. Deletions of the endocytic components VPS28 and VPS32 in Candida albicans lead to echinocandin and azole hypersensitivity.
Cornet M; Gaillardin C; Richard ML
Antimicrob Agents Chemother; 2006 Oct; 50(10):3492-5. PubMed ID: 17005841
[TBL] [Abstract][Full Text] [Related]
31. Nanoscale effects of caspofungin against two yeast species, Saccharomyces cerevisiae and Candida albicans.
Formosa C; Schiavone M; Martin-Yken H; François JM; Duval RE; Dague E
Antimicrob Agents Chemother; 2013 Aug; 57(8):3498-506. PubMed ID: 23669379
[TBL] [Abstract][Full Text] [Related]
32. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans.
Feldmesser M; Kress Y; Mednick A; Casadevall A
J Infect Dis; 2000 Dec; 182(6):1791-5. PubMed ID: 11069257
[TBL] [Abstract][Full Text] [Related]
33. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.
Jacobsen MD; Whyte JA; Odds FC
Antimicrob Agents Chemother; 2007 May; 51(5):1882-4. PubMed ID: 17307974
[TBL] [Abstract][Full Text] [Related]
34. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments.
Clancy CJ; Huang H; Cheng S; Derendorf H; Nguyen MH
Antimicrob Agents Chemother; 2006 Jul; 50(7):2569-72. PubMed ID: 16801448
[TBL] [Abstract][Full Text] [Related]
35. A whole-cell Candida albicans assay for the detection of inhibitors towards fungal cell wall synthesis and assembly.
Frost DJ; Brandt KD; Cugier D; Goldman R
J Antibiot (Tokyo); 1995 Apr; 48(4):306-10. PubMed ID: 7775267
[TBL] [Abstract][Full Text] [Related]
36. The echinocandins.
Cappelletty D; Eiselstein-McKitrick K
Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
[TBL] [Abstract][Full Text] [Related]
37. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates.
Beyda ND; Liao G; Endres BT; Lewis RE; Garey KW
Antimicrob Agents Chemother; 2015 Sep; 59(9):5405-12. PubMed ID: 26100700
[TBL] [Abstract][Full Text] [Related]
38. Functional analysis of Candida albicans GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivity.
Plaine A; Walker L; Da Costa G; Mora-Montes HM; McKinnon A; Gow NA; Gaillardin C; Munro CA; Richard ML
Fungal Genet Biol; 2008 Oct; 45(10):1404-14. PubMed ID: 18765290
[TBL] [Abstract][Full Text] [Related]
39. In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus.
Ganesan LT; Manavathu EK; Cutright JL; Alangaden GJ; Chandrasekar PH
Clin Microbiol Infect; 2004 Nov; 10(11):961-6. PubMed ID: 15521997
[TBL] [Abstract][Full Text] [Related]
40. Efg1 and Cas5 Orchestrate Cell Wall Damage Response to Caspofungin in Candida albicans.
Xiong K; Su C; Sun Q; Lu Y
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
